{"id":7002,"date":"2026-04-25T12:21:39","date_gmt":"2026-04-25T10:21:39","guid":{"rendered":"https:\/\/mediconomics.com\/?post_type=glossary&p=7002"},"modified":"2026-09-07T11:56:36","modified_gmt":"2026-09-07T09:56:36","slug":"gcp-inspection","status":"publish","type":"glossary","link":"https:\/\/mediconomics.com\/en\/glossar\/gcp-inspection\/","title":{"rendered":"GCP Inspection"},"content":{"rendered":"

A GCP inspection is a regulatory or competent-authority-commissioned review of whether a clinical trial is planned, conducted, monitored, documented and reported in accordance with the principles of Good Clinical Practice (GCP). The focus is on patient safety, data integrity and the traceability of all trial-relevant processes. Inspections can involve the sponsor, CRO, investigational site, laboratory, data management service provider or archiving service provider. <\/p>\n

GCP inspections are not an \u201caudit\u201d within internal quality management but a regulatory oversight measure. Results can range from minor observations to critical findings that can affect the usability of data, the continuation of a trial, or authorisation decisions. <\/p>\n

Triggers and types of GCP inspections<\/h2>\n

Inspections can take place routinely, on a risk basis, or for cause, for example in the event of suspected serious deviations, data anomalies or complaints. They are also often part of authorisation procedures (e.g. to verify pivotal trials or specific investigational sites). In the EU, inspections are coordinated by national authorities depending on jurisdiction (e.g. BfArM, PEI); internationally, FDA inspections are among the relevant ones. <\/p>\n

A distinction is made, among others, between inspections at the sponsor (system- and trial-specific), inspections at investigational sites (site inspections) and inspections at outsourced service providers. Remote elements are also common, e.g. document reviews via secure data rooms, supplemented by on-site visits for source documents and infrastructure. <\/p>\n

Areas of review: what authorities typically assess<\/h2>\n

Authorities assess whether the trial complies with the approved protocol and applicable requirements. Typical areas of review include: informed consent, protection of particularly vulnerable persons, delineation of roles and responsibilities between sponsor, CRO and investigational site, qualification of personnel, data flow and data management, handling of protocol deviations, medicinal product safety (e.g. SAE\/SUSAR processes), and the completeness of essential documents in the Trial Master File. <\/p>\n

At the investigational site, the focus is usually on the documentation in the Investigator Site File, the completeness and plausibility of the source data, investigational medicinal product logistics and the implementation of monitoring. For central systems, the validation of computerized systems and the integrity of the audit trail may also be reviewed. In sponsor\/CRO inspections, vendor management, evidence of oversight and change control also come into focus. <\/p>\n

Process: preparation, conduct, follow-up<\/h2>\n

Before the inspection, affected parties usually receive an announcement with the scope, schedule and requested documents. In preparation, a structured document package, the appointment of an inspection team, a clear line of communication and a realistic \u201cmock inspection\u201d are helpful. It is important that statements are consistent and that documents are readily available. <\/p>\n

The conduct usually includes an opening meeting, interviews, document and data reviews, a walk-through if necessary (e.g. storage of investigational medicinal products) and a closing meeting with preliminary observations. The follow-up often involves an inspection report or a follow-up letter with findings, for which CAPA measures and deadlines are expected. <\/p>\n

Role of sponsor and CRO<\/h2>\n

Since many tasks are outsourced, governance is crucial: the sponsor remains responsible, while the CRO is generally responsible for the operational implementation of central processes. An inspection therefore checks whether oversight is documented, whether vendor management is functioning and whether responsibilities are consistently reflected in contracts, SOPs and delegated tasks. <\/p>\n

For CROs, it is particularly relevant that monitoring reports, query management, training records and process documentation are consistent. Common weaknesses include insufficient documentation of decisions, incomplete tracking of deviations or gaps in archiving. A robust \u201cevidence trail\u201d makes it easier to answer detailed questions, especially when multiple systems (EDC, eTMF, safety DB) are involved. <\/p>\n

Typical findings, prevention and references<\/h2>\n

The most common findings include deficiencies in consent documentation, late safety reports, missing evidence of qualification\/training, insufficient source data verification, and inconsistencies between the eCRF and source documents. Also critical are a lack of version control for documents, incomplete delegation logs and unclear responsibilities for outsourced activities. <\/p>\n

Clear SOPs, risk-based quality planning, an up-to-date Trial Master File, and regular internal audits and quality controls have a preventive effect. In the event of deviations, root-cause analyses and CAPA measures should be documented and followed up promptly so that they can be proven effective in an inspection. To ensure inspection readiness, it has also proven useful to design processes to be \u201cinspection-ready\u201d: clear responsibilities, consistent document control, timely filing in the eTMF and a traceable audit trail in all relevant systems. <\/p>\n

Especially in complex trial landscapes with many service providers, it should be traceable how oversight is practiced, e.g. through documented quality metrics, risk reviews, escalation paths and decisions on deviations. The training of new team members, the versioning of SOPs and the control of system access are also regularly used in inspections as indicators of a functioning quality management system. <\/p>\n